Discontinuation of GLP-1 receptor agonists suggested before conception rather than between start of pregnancy and end of first trimester<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, July 18, 2025 (HealthDay News) — In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for <\/strong>pregnancy care in individuals with preexisting diabetes mellitus (PDM). The guidelines were published online July 14 in the Journal of Clinical Endocrinology & Metabolism <\/em>to coincide with presentation at ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.<\/p>\n Jennifer A. Wyckoff, M.D., from the University of Michigan in Ann Arbor, and colleagues developed recommendations for the care of individuals with PDM before, during, and after pregnancy.<\/p>\n The authors suggest asking a screening question about pregnancy intention for individuals with diabetes mellitus who have the possibility of becoming pregnant, with contraception suggested when pregnancy is not desired. Discontinuation of glucagon-like peptide-1 receptor agonists is suggested before conception — rather than between the start of pregnancy and the end of the first trimester — in individuals with type 2 diabetes mellitus (T2DM). Routine addition of metformin is not suggested in pregnant individuals with T2DM already on insulin. Either a carbohydrate-restricted diet (<175 g\/day) or usual diet (>175 g\/day) is suggested during pregnancy in individuals with PDM. Use of a continuous glucose monitor (CGM) or self-monitoring of blood glucose is suggested in pregnant individuals with T2DM. For individuals with PDM using a CGM, use of a single 24-hour CGM target <140 mg\/dL is not suggested in place of standard-of-care pregnancy glucose targets. A hybrid closed-loop pump is suggested rather than an insulin pump with CGM for individuals with type 1 diabetes mellitus who are pregnant.<\/p>\n “We developed these guidelines as diabetes rates are rising among women of reproductive age and very few women with diabetes receive proper preconception care,” Wyckoff said in a statement.<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry; two authors disclosed ties to Dexcom.<\/p>\n